Adalimumab in Vogt-Koyanagi-Harada Disease Refractory to Conventional Therapy

Adalimumab in Vogt-Koyanagi-Harada Disease Refractory to Conventional Therapy

Background: No study explores the effectiveness of adalimumab in sight-threatening Vogt-Koyanagi-Harada (VKH) patients in China.Objective: To evaluate the short-term effectiveness and safety of adalimumab (ADA) in patients with sight-threatening Vogt-Koyanagi-Harada (VKH) disease refractory to conve...

Full description

Bibliographic Details
Main Authors: Shizhao Yang, Tianyu Tao, Zhaohao Huang, Xiuxing Liu, He Li, Lihui Xie, Feng Wen, Wei Chi, Wenru Su
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-01-01
Series:Frontiers in Medicine
Subjects:
adalimumab
TNF-α inhibitor
Vogt-Koyanagi-Harada (VKH)
refractory
treatment
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2021.799427/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2021.799427/full

Similar Items